Protagonist Therapeutics (PTGX) Reports Q4 Loss of $0.15
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as oil gains curb risk appetite after S&P record close
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- Reddit to join S&P 500 index on Aug. 18, shares leap
Protagonist Therapeutics (PTGX) PT Trimmed to $42 at BMO Capital, But Sees Catalyst-Rich 2018
March 8, 2018 5:47 AM ESTBMO Capital analyst M. Ian Somaiya lowered his price target on Protagonist Therapeutics (NASDAQ: PTGX) to $42.00 (from $44.00) while maintaining an Outperform rating.
Somaiya notes Protagonists low risk pipeline is quickly maturing with an interim analysis (futility) of the Phase 2b... More
